These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38361006)

  • 1. EfficientNet-Based System for Detecting EGFR-Mutant Status and Predicting Prognosis of Tyrosine Kinase Inhibitors in Patients with NSCLC.
    Xu N; Wang J; Dai G; Lu T; Li S; Deng K; Song J
    J Imaging Inform Med; 2024 Jun; 37(3):1086-1099. PubMed ID: 38361006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study.
    Wang S; Yu H; Gan Y; Wu Z; Li E; Li X; Cao J; Zhu Y; Wang L; Deng H; Xie M; Wang Y; Ma X; Liu D; Chen B; Tian P; Qiu Z; Xian J; Ren J; Wang K; Wei W; Xie F; Li Z; Wang Q; Xue X; Liu Z; Shi J; Li W; Tian J
    Lancet Digit Health; 2022 May; 4(5):e309-e319. PubMed ID: 35341713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database.
    Okuma Y; Shintani Y; Sekine I; Shukuya T; Takayama K; Inoue A; Okamoto I; Kiura K; Yamamoto N; Kawaguchi T; Miyaoka E; Yoshino I; Date H
    Clin Lung Cancer; 2024 Jun; 25(4):336-346.e2. PubMed ID: 38360497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
    Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
    Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis.
    Qi H; Hou Y; Zheng Z; Zheng M; Sun X; Xing L
    Clin Radiol; 2024 Jul; 79(7):515-525. PubMed ID: 38637187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.
    Hsiao SH; Liu HE; Lee HL; Lin CL; Chen WY; Wu ZH; Lin SE; Chiang LL; Chung CL
    PLoS One; 2013; 8(12):e83266. PubMed ID: 24376677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Habitat radiomics and deep learning fusion nomogram to predict EGFR mutation status in stage I non-small cell lung cancer: a multicenter study.
    Wu J; Meng H; Zhou L; Wang M; Jin S; Ji H; Liu B; Jin P; Du C
    Sci Rep; 2024 Jul; 14(1):15877. PubMed ID: 38982267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.
    Li Y; Lv X; Wang Y; Xu Z; Lv Y; Hou D
    Eur Radiol Exp; 2023 Nov; 7(1):64. PubMed ID: 37914925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.
    Nishino M; Dahlberg SE; Cardarella S; Jackman DM; Rabin MS; Ramaiya NH; Hatabu H; Jänne PA; Johnson BE
    Cancer; 2013 Nov; 119(21):3761-8. PubMed ID: 23922022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
    Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):287-293. PubMed ID: 32761377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand.
    Aye PS; Tin Tin S; McKeage MJ; Khwaounjoo P; Cavadino A; Elwood JM
    BMC Cancer; 2020 Jul; 20(1):658. PubMed ID: 32664868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Qu J; Zhang T; Zhang X; Zhang W; Li Y; Gong Q; Yao L; Lui S
    Clin Radiol; 2024 Apr; 79(4):e582-e591. PubMed ID: 38310058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy.
    Lv P; Yang S; Liu W; Qin H; Tang X; Wu F; Liu Z; Gao H; Liu X
    Thorac Cancer; 2020 Jan; 11(1):29-40. PubMed ID: 31691525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung.
    Kuo CY; Tsai MJ; Hung JY; Lee MH; Wu KL; Tsai YC; Chuang CH; Huang CW; Chen CL; Yang CJ; Chong IW
    Kaohsiung J Med Sci; 2024 May; 40(5):467-476. PubMed ID: 38523603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
    Sari M; Aydiner A
    J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.